Feasibility of Therapy With Hypomethylating Agents in Patients With Renal Insufficiency

Silverman, 2002, Randomized controlled trial of azacitidine in patients with the myelodysplastic syndrome: a study of the Cancer and Leukemia Group B, J Clin Oncol, 20, 2429, 10.1200/JCO.2002.04.117 Fenaux, 2007, Azacitidine (AZA) treatment prolongs overall survival (OS) in higher-risk MDS patients compared with conventional cure regimens (CCR): results of the AZA-001 phase III study, Blood, 110, 250a, 10.1182/blood.V110.11.817.817 Kantarjian, 2006, Decitabine improves patient outcomes in myelodysplastic syndromes: results of a phase III randomized study, Cancer, 106, 1794, 10.1002/cncr.21792 Kantarjian, 2007, Results of a randomized study of 3 schedules of low-dose decitabine in higher-risk myelodysplastic syndrome and chronic myelomonocytic leukemia, Blood, 109, 52, 10.1182/blood-2006-05-021162 Rhee, 2002, DNMT1 and DNMT3b cooperate to silence genes in human cancer cells, Nature, 416, 552, 10.1038/416552a Momparler, 1979, Kinetics of phosphorylation of 5-aza-2-deoxycytidine by deoxycytidine kinase, Biochem Pharmacol, 28, 1443, 10.1016/0006-2952(79)90454-4 Chabot, 1984, Antileukemic activity of 5-aza-2’-deoxycytidine and cytarabine against intracerebral L1210 murine leukemia, Cancer Treat Rep, 68, 1483 Lyons, 2003, Decitabine: Development of a DNA methyltransferase inhibitor for hematological malignancies, Curr Opin Investig Drugs, 4, 1442 Marcucci, 2005, Bioavailability of Azacitidine Subcutaneous Versus Intravenous in Patients With the Myelodysplastic Syndromes, J Clin Pharmacol, 45, 597, 10.1177/0091270004271947 Peterson, 1981, 5-Azacytidine and renal tubular dysfunction, Blood, 57, 182, 10.1182/blood.V57.1.182.182 Aronoff, 2007 Demirovic, 2009, Estimation of creatinine clearance in morbidly obese patients, Am J Health Syst Pharm, 66, 642, 10.2146/ajhp080200 Kantarjian, 2006, Survival advantage with decitabine versus intensive chemotherapy in patients with higher risk myelodysplastic syndrome: comparison with historical experience, Cancer, 106, 1794, 10.1002/cncr.21792 Cheson, 2006, Clinical application and proposal for modification of the International Working Group (IWG) response criteria in myelodysplasia, Blood, 108, 419, 10.1182/blood-2005-10-4149 Garcia-Manero, 2006, Phase 1/2 study of the combination of 5-aza-2-deoxycytidine with valproic acid in patients with leukemia, Blood, 108, 3271, 10.1182/blood-2006-03-009142